Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat models

The objective of this study was to examine the effect of a high fat meal and hyperlipidemia on the pharmacokinetic behavior of amiodarone. To evaluate these effects, single doses of amiodarone were administered to rats i.v. (25 mg/kg) or orally (50 mg/kg). Some rats were rendered hyperlipidemic by intraperitoneal doses of poloxamer 407 followed by amiodarone i.v. In other normolipidemic rats, amiodarone was administered i.v. in a fasted state or after the administration of 1% cholesterol in peanut oil. Amiodarone plasma concentrations were considerably (>11‐fold) increased in hyperlipidemia. Substantial decreases were noted in the clearance, volume of distribution and unbound fraction (11.6, 23 and 24.7‐fold, respectively) in plasma of hyperlipidemic rats. Oral lipid caused a significant increase in plasma AUC0−∞ (1.38‐fold) and a significant decrease in clearance (1.5‐fold) of amiodarone after intravenous doses. Oral consumption of 1% cholesterol in peanut oil significantly increased the plasma AUC (1.83‐fold) and bioavailability of amiodarone (1.31‐fold) after oral doses. In determining oral bioavailability of lipophilic drugs such as amiodarone in food effect studies, in addition to the increase in absorption of drugs, other factors such as a decrease in clearance due to increases in lipoprotein levels should be taken into account. Copyright © 2005 John Wiley & Sons, Ltd.

[1]  T. Johnston,et al.  Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. , 1992, Journal of pharmaceutical sciences.

[2]  S. Nattel,et al.  Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. , 1987, Circulation.

[3]  E. Riva,et al.  Pharmacokinetics of Amiodarone in Rats , 1982, Journal of cardiovascular pharmacology.

[4]  K. Williams,et al.  Therapeutic drug monitoring: antiarrhythmic drugs. , 1998, British journal of clinical pharmacology.

[5]  G. Edwards,et al.  Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. , 1998, Journal of pharmaceutical sciences.

[6]  T. Bouillon,et al.  Population pharmacokinetics of long‐term oral amiodarone therapy , 2000, Clinical pharmacology and therapeutics.

[7]  D. Brocks,et al.  The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. , 2002, Journal of pharmaceutical sciences.

[8]  C. Klaassen,et al.  Mechanisms of bile formation, hepatic uptake, and biliary excretion. , 1984, Pharmacological reviews.

[9]  M. Lalloz,et al.  Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands , 1984, The Journal of pharmacy and pharmacology.

[10]  P. Wyss,et al.  Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[11]  G. Hollander,et al.  Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. , 2004, Chest.

[12]  Y. Yim,et al.  Characterization of amiodarone metabolites and impurities using liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.

[13]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[14]  T. Johnston The P-407–Induced Murine Model of Dose-Controlled Hyperlipidemia and Atherosclerosis: A Review of Findings To Date , 2004, Journal of cardiovascular pharmacology.

[15]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[16]  A. Auricchio,et al.  New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. , 1999, The American journal of cardiology.

[17]  T. Johnston,et al.  Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. , 1993, Biochemical pharmacology.

[18]  J. Kharidia,et al.  Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. , 1996, Biopharmaceutics & drug disposition.

[19]  J. Mason Drug therapy: amiodarone , 1987 .

[20]  P. Tso,et al.  Effect of fat pre-feeding on bile flow and composition in the rat. , 1991, Biochimica et biophysica acta.

[21]  G. Naccarelli,et al.  Amiodarone: What have we learned from clinical trials? , 2000, Clinical cardiology.

[22]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[23]  J. Heubi,et al.  Adaptive response of the enterohepatic circulation of bile acids to extrahepatic cholestasis , 1996, Hepatology.

[24]  P. Bjerregaard,et al.  Pharmacokinetics of amiodarone after intravenous and oral administration , 1981, European Journal of Clinical Pharmacology.

[25]  J. Schuhmacher,et al.  Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. , 2000, Journal of pharmaceutical sciences.

[26]  G. Tognoni,et al.  Clinical Pharmacokinetics of Amiodarone , 1984, Clinical pharmacokinetics.

[27]  G. Naccarelli,et al.  Amiodarone: clinical trials. , 2000, Current opinion in cardiology.

[28]  I Weinryb,et al.  Bioavailability of amiodarone tablets administered with and without food in healthy subjects. , 2001, The American journal of cardiology.